HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The CD40 agonist antibody CP-870,893 enhances dendritic cell and B-cell activity and promotes anti-tumor efficacy in SCID-hu mice.

Abstract
CD40 is a member of the TNF family of receptors that has been shown to play a crucial role in enhancing dendritic cell activity and fostering anti-tumor immune responses. In this study, we demonstrate the in vitro properties and in vivo efficacious activity of the CD40 agonist antibody, CP-870,893. CP-870,893 is a fully human, IgG2 antibody that selectively interacts with CD40 at a site distinct from its ligand-binding region with a KD of 0.4 nM. It enhances the expression of MHC class II, CD54, CD86, and CD23 on human B cells in vitro. CP-870,893 also enhances dendritic cell activity as evidenced by cytokine secretion (IL-12, IL-23, IL-8), the upregulation of CD86 and CD83, and the ability to prime T cells to secrete IFNγ. In SCID-beige mice, a single parenteral injection of CP-870,893 was therapeutically effective against several CD40(pos) human tumors (B-cell lymphoma, breast, colon, and prostate) indicating direct effects on tumor cell survival and/or growth. When mice were co-implanted with human T cells and dendritic cells, the activity of CP-870,893 against CD40(pos) tumors increased, and efficacy was also observed against CD40(neg) and CD40(low) tumors demonstrating the ability of CP-870,893 to enhance anti-tumor immune function in vivo. These studies suggest that CP-870,893 has the potential to be efficacious against a wide range of tumor types through both direct and immune-mediated effects.
AuthorsRonald P Gladue, Timothy Paradis, Susan H Cole, Carol Donovan, Robin Nelson, Robbin Alpert, Joe Gardner, Ed Natoli, Eileen Elliott, Richard Shepard, Vahe Bedian
JournalCancer immunology, immunotherapy : CII (Cancer Immunol Immunother) Vol. 60 Issue 7 Pg. 1009-17 (Jul 2011) ISSN: 1432-0851 [Electronic] Germany
PMID21479995 (Publication Type: Journal Article)
Chemical References
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • CD40 Antigens
  • Cytokines
  • selicrelumab
Topics
  • Animals
  • Antibodies, Monoclonal (physiology)
  • Antibodies, Monoclonal, Humanized
  • B-Lymphocytes (cytology, immunology)
  • CD40 Antigens (immunology)
  • Cells, Cultured
  • Cytokines (metabolism)
  • Dendritic Cells (cytology, immunology)
  • Flow Cytometry
  • Humans
  • Lymphocyte Activation
  • Mice
  • Mice, SCID
  • Neoplasms, Experimental (immunology, prevention & control)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: